Top Markets
#1 GEKKO GEKKO +52.86%
#2 TENDIES TENDIES +49.51%
#3 Helium Helium +48.71%
#4 Pons Pons +43.17%
#5 ADO Protocol ADO Protocol +39.18%
#6 Prom Prom +31.04%
#7 Collector Crypt Collector Crypt +24.28%
#8 Nillion Nillion +19.84%
#9 龙虾 (Lobster) 龙虾 (Lobster) +19.38%
#10 o1.exchange o1.exchange +18.11%
Coin of the day
GEKKO GEKKO
Tetapan
Bahasa
MALAY
Mata wang
USD
Tema
Provention Bio, Inc. Provention Bio, Inc.

Provention Bio, Inc.

PRVB
Kedudukan dalam Saham #9449
Provention Bio, Inc. is a clinical-stage biopharmaceutical firm dedicated to... Provention Bio, Inc. is a clinical-stage biopharmaceutical firm dedicated to discovering and bringing to market therapies aimed at intercepting and preventing autoimmune disorders. Their lead investigational candidate, PRV-031 (teplizumab, a monoclonal antibody), is currently in a Phase III clinical trial for the interception of Type 1 Diabetes (T1D). Another asset, PRV-3279, has successfully completed its Phase Ib clinical trial for the treatment of lupus. The company is also developing PRV-101, a vaccine targeting coxsackie virus B (CVB) to prevent both acute CVB infections and the onset of T1D. Additionally, PRV-015 is undergoing a Phase IIb clinical trial, offering a potential treatment for celiac disease that does not respond to a gluten-free diet. Provention Bio has established strategic partnerships to advance its pipeline. This includes a licensing and collaboration agreement with Amgen Inc. for PRV-015, described as a novel anti-IL-15 monoclonal antibody, for the continued development against gluten-free diet non-responsive celiac disease. Furthermore, a strategic alliance with Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd. focuses on the development and commercialization of PRV-3279 in Greater China. PRV-3279 is characterized as a bispecific antibody-based molecule designed to target B cell surface proteins CD32B and CD79B. Founded in 2016, Provention Bio, Inc. maintains its headquarters in Red Bank, New Jersey.
Harga Saham
$24.98
Disegerakkan terakhir: 2023-04-27
Modal Pasaran
$1.01B
Perubahan (1 hari)
0.00%
Perubahan (1 tahun)
0.00%
Negara
US
Perdagangan Provention Bio, Inc. (PRVB)

Kategori

Healthcare
Nisbah P/E bagi Provention Bio, Inc. (PRVB)
Nisbah P/E pada 2026 TTM: 0
Menurut laporan kewangan dan harga saham terkini Provention Bio, Inc., nisbah P/E semasa (TTM) ialah 0. Pada akhir 2026, syarikat mempunyai nisbah P/E sebanyak 0.
Sejarah nisbah P/E bagi Provention Bio, Inc. dari 2026 hingga 2026
Nisbah P/E pada akhir setiap tahun
Tahun Nisbah P/E Ubah
Tidak cukup data untuk tarikh yang disediakan.
Nisbah P/E untuk syarikat serupa atau pesaing
Syarikat Nisbah P/E Perbezaan Nisbah P/E Negara
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
 29.20 -
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
 30.62 -
NL
CSL Limited CSL Limited
CSL Limited
CSL.AX
 32.46 -
AU
Moderna, Inc. Moderna, Inc.
Moderna, Inc.
MRNA.US
 -7.93 -
US
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
 - -
CH
Cara membaca nisbah P/E

Nisbah Harga/Perolehan (P/E) mengukur hubungan antara harga saham syarikat dan pendapatan sesaham.
P/E yang rendah tetapi positif menunjukkan syarikat menjana keuntungan tinggi berbanding dengan penilaian semasa dan mungkin dinilai rendah. P/E negatif yang tinggi (hampir 0) menunjukkan kerugian besar.

Syarikat dengan P/E melebihi 30 atau negatif biasanya dilihat sebagai "saham pertumbuhan", bermaksud pelabur menjangkakan pertumbuhan atau keuntungan masa depan.

Syarikat dengan P/E positif di bawah 10 biasanya dianggap sebagai "saham nilai", bermaksud syarikat sudah menguntungkan dan tidak dijangka berkembang pesat.